(Incorporated in Singapore with Unique Entity No.: 201424579Z)
website: **www.ughealthcarecorporation.com**
SGX stock code: **8K7**

UG Healthcare returns to profitability with S$2.1 million in net profit in FY26

- The Group's integrated OBM supply chain has bolstered its resilience to challenges and enabled a recovery in profitability by enhancing operational efficiency, partnering with cost-effective manufacturers, reinforcing its proprietary international brand, and maintaining a strong market presence in key markets across both developed and developing countries.
- The notable increase in EBITDA for FY26 was driven by favourable market dynamics and enhanced process efficiency across both upstream and downstream operations.
- The Group is well-positioned to sustain its growth momentum by capitalising on the increasing global demand for hand protection solutions and hygiene consumables across the industrial and healthcare sectors.

KEY FINANCIAL HIGHLIGHTS

FYE 30 Jun (S$' mil)	**2H FY26** (unaudited)	**2H FY25** (unaudited)	YoY Change	**FY26** (unaudited)	**FY25** (audited)	YoY Change
Revenue	**76.14**	71.41	*6.6%*	**150.82**	144.07	*4.7%*
Gross profit	**24.54**	15.91	*54.2%*	**42.87**	34.74	*23.4%*
Gross margin	**32.2%**	22.3%	*9.9pp*	**28.4%**	24.1%	*4.3pp*
EBITDA[(1)]	**9.11**	0.93	*>100.0%*	**12.40**	2.17	*>100.0%*
Profit / (Loss) before tax	**4.94**	(2.50)	*N.M.*	**4.00**	(3.74)	*N.M.*
Profit / (loss) after tax	**4.06**	(2.64)	*N.M.*	**2.65**	(4.72)	*N.M.*
Net profit / (loss) [(2)]	**3.24**	(3.16)	*N.M.*	**2.10**	(4.10)	*N.M.*
EPS / (LPS) [(3)] (cents)	**0.52**	(0.51)	*N.M.*	**0.34**	(0.66)	*N.M.*

Notes:

* 2H denotes 6 months and FY denotes 12 months ended 30 June; pp denotes percentage points; N.M. denotes not meaningful.

(1) Earnings before interest, taxes, depreciation, and amortisation ("**EBITDA**") is a measure of a company's operating profitability, by using profit/(loss) before tax and adding back interest expense, depreciation, and amortisation of intangible assets.

(2) Net profit / (loss) attributable to owners of the Company.

(3) Earnings per share ("**EPS**") and loss per share ("**LPS**") were computed based on the weighted average number of shares of 623.8 million for 2H FY26, 2H FY25, FY26, and FY25.

SINGAPORE, 26 August 2026 – SGX Catalist-listed **UG Healthcare Corporation Limited** 优格医疗集团 ("**UG Healthcare**" and together with its subsidiaries, the "**Group**"), an own brand manufacturer ("**OBM**") that markets and sells proprietary **UNI**GLOVES® branded products through its established global downstream distribution network, returned to profitability with a net profit of S$2.1 million in FY26, a reversal from a net loss of S$4.1 million in FY25. This set of commendable results was primarily driven by higher sales volume and improved average selling price ("**ASP**") for disposable examination

gloves and other ancillary products, supported by the expanded global distribution network and the strong proprietary international **UNI**GLOVES® brand in key markets; along with better operational efficiency and prudent resource management.

In response to the Group's FY26 financial performance, Mr. Lee Jun Yih, Joint CEO, Executive Director and Finance Director of UG Healthcare, said, **"Our commitment to an integrated OBM supply chain business approach continues to strengthen our resilience against industry challenges, as well as macroeconomic and geopolitical uncertainties, while facilitating our recovery in profitability.**

Our well-established and extensive global distribution network, spanning both developed and developing countries, offers valuable market intelligence. This gives us the flexibility to collaborate with cost-effective manufacturers under our proprietary international UNIGLOVES® brand while maintaining the production of premium-quality disposable examination gloves at our upstream manufacturing facilities. This strategy allows us to broaden our product portfolio with a comparative advantage as well as market diversification.

Our EBITDA for FY26 increased significantly, driven by favourable market dynamics and the positive impact of our continued process efficiency initiatives across both upstream and downstream operations. This encouraging trend reinforces our commitment to innovation and operational excellence."

Published in July 2026, Precedence Research estimates that the global disposable gloves market was valued at USD 11.21 billion in 2025. It is projected to grow from USD 12.15 billion in 2026 to approximately USD 24.92 billion by 2035, achieving a compound annual growth rate of 8.32% between 2026 and 2035. This market growth is driven by strategic alliances, commitments to sustainability, increased hygiene awareness, and rising demand in the manufacturing and healthcare sectors.
Source: https://www.precedenceresearch.com/disposable-gloves-market

Mr. Lee adds, **"While our OBM supply chain strategy required considerable time for development and refinement, it continues to yield positive results, particularly in strengthening customer confidence in product quality and traceability. This strategy reflects our commitment to keeping our end users safe with our hand protection solutions and hygiene consumables.**

Looking ahead, we remain focused on enhancing operational efficiency to sustain our growth momentum by capitalising on the increasing global demand for hand protection solutions and hygiene consumables in the industrial and healthcare sectors. Simultaneously, we will continue

to exercise caution in resource management and remain vigilant in identifying opportunities in light of current macroeconomic and geopolitical uncertainties."

FINANCIAL REVIEW

The Group achieved a revenue growth of 4.7%, increasing from S$144.1 million in FY25 to S$150.8 million in FY26. This was attributable to higher sales volume and an increase in ASP of disposable gloves, driven by the Group's downstream global distribution network.

REVENUE ANALYSIS BY PRODUCT SEGMENTS

FYE 30 Jun (S$' mil)	Revenue			Gross Profit			Gross Margin	
	FY26	FY25	Variance	**FY26**	FY25	Variance	**FY26**	FY25
Latex examination gloves	**66.67**	61.27	8.8%	**19.90**	15.73	26.6%	**29.9%**	25.7%
Nitrile examination gloves	**67.44**	66.32	1.7%	**18.73**	15.69	19.4%	**27.8%**	23.7%
Other ancillary products	**16.71**	16.48	1.4%	**4.24**	3.32	27.5%	**25.3%**	20.2%
Group total	**150.82**	**144.07**	**4.7%**	**42.87**	**34.74**	**23.4%**	**28.4%**	**24.1%**

The Group's extensive downstream global distribution network, coupled with its strong proprietary international branding, has driven growth in sales volume, while rising ASP and improved operational efficiency led to higher revenue and gross profits across all product segments.

REVENUE ANALYSIS BY KEY MARKETS

FYE 30 June (S$' mil)	1H FY26	2H FY26	FY26	FY25	Variance (%)
Europe	44.92	48.13	**93.05**	88.05	5.7
North America	3.58	5.19	**8.77**	11.04	(20.5)
South America	6.32	4.06	**10.38**	11.96	(13.2)
Africa	6.32	4.24	**10.56**	8.22	28.5
Asia	11.51	12.36	**23.87**	22.38	6.7
Others	2.03	2.16	**4.19**	2.43	72.2
Group total	**74.68**	**76.14**	**150.82**	**144.07**	**4.7**

Note: As a result of the integrated supply chain, the Group recognises sales only after the products have been sold by the distribution companies. The goods in transit and in the warehouses of its distribution companies are recorded as inventory, and can only be recognised as revenue when they are sold to end consumers.

Through its OBM supply chain business platform, the Group continues to strengthen its robust market presence in key regions, including Europe and Asia, in FY26. This strategic enhancement of market presence boosts operational efficiency and allows the Group to address evolving needs of its customers more effectively.

In light of geopolitical and tariff uncertainties, the Group emphasised its flexibility in collaborating with cost-effective manufacturers to expand its product portfolio produced under the proprietary international **UNI**GLOVES® brand. In addition, it prioritised prudent cost management and enhanced operational efficiency to control costs of sales. Consequently, the Group's gross profit rose by 23.4% year-on-year, increasing from S$34.7 million in FY25 to S$42.9 million in FY26. This increase was in tandem with the increase in sales revenue, though it was partially offset by higher depreciation expenses of the production lines in the third manufacturing facility, which has recently commenced trial production. Accordingly, the Group's composite gross margin improved from 24.1% in FY25 to 28.4% in FY26.

The Group recorded other income of S$1.0 million in FY26, mainly due to a reversal of impairment on property, plant and equipment of S$1.3 million, interest income of S$0.6 million, and a gain on disposal of assets of S$0.2 million. The increase in other income was partially offset by a loss allowance on trade receivables of S$1.4 million.

The Group reported a net profit attributable to owners of the Company of S$2.1 million in FY26, representing a turnaround from a net loss attributable to owners of the Company of S$4.1 million in FY25, after accounting for operating expenses, finance cost, share of profits from joint venture, tax expenses, and minority interests.

FINANCIAL POSITION ANALYSIS

FYE 30 June (S$' mil)	**As at 30 June 2026**	**As at 30 June 2025**	Variance (%)
Equity attributable to owners of the Company ("**Net asset value**")	**171.76**	162.75	5.5
Cash and bank balances	**27.41**	23.29	17.7
Short-term bank borrowings	**20.67**	24.26	(14.8)
Long-term bank borrowings	**18.57**	22.50	(17.5)
Gearing ratio (1)	**22.8%**	28.7%	(5.9) pp
Net asset value per share (2)	**S$0.2753**	S$0.2609	5.5

Notes:

(1) Gearing ratio was computed using total debt over equity attributable to owners of the Company.

(2) Net asset value per share was computed based on the share capital of approximately 623.8 million shares as at 30 June 2026 and 30 June 2025.

The Group's balance sheet remained robust, with net asset value increasing from S$162.8 million as at 30 June 2025 to S$171.8 million as at 30 June 2026. The increase was primarily due to net earnings generated and the positive foreign-currency translation movement during the year in FY26.

Correspondingly, net asset value per share increased from S$0.2609 to S$0.2753 over the same period.

Meanwhile, the Group's third manufacturing facility has begun trial production. The Group expects to progressively commercialise the facility in Q1 calendar year 2027, marking the start of the second half of the financial year ending 30 June 2027 ("**2H FY27**"). The Company will update shareholders on material developments of the Group as and when appropriate.

###

This media release is to be read in conjunction with the Company's results announcement posted on the SGX website on 26 August 2026.

UG HEALTHCARE CORPORATION 优格医疗集团
(Stock Code – SGX: **8K7** | Bloomberg: **UGHC SP** | Reuters: **UGHE.SI**)

UG Healthcare Corporation Limited ("**UG Healthcare**" and together with its subsidiaries, the "**Group**") is an own brand manufacturer that specialises in the marketing and sale of proprietary **UNI**GLOVES® branded hand protection solutions, as well as non-glove hygiene and healthcare ancillary products through its own established global downstream distribution network.

The Group owns and operates an extensive downstream network of distribution companies with a local presence in Europe, the United Kingdom, the USA, China, Africa, North America, and South America, where it primarily markets and sells its proprietary **UNI**GLOVES® portfolio of both disposable and reusable hand protection solutions and non-glove hygiene consumables. These disposable and reusable hand protection products are used across a diverse range of industries that require safety and cross-infection protection and high hygiene standards, as well as catering to different applications and preferences. Along with its range of non-glove hygiene ancillary products, the Group aims to address infection control, hygiene and care, dental care, and wound care across diverse industries.

The downstream distribution division is supported and complemented by the Group's own upstream manufacturing division, manufacturing natural latex and nitrile disposable gloves under its **UNI**GLOVES® brand and third-party labels in its upstream manufacturing facilities located in Malaysia. The Group's upstream manufacturing is certified by the British Standards Institution for ISO 9001:2015, ISO 13485:2016 and EN ISO 13485:2016 for the scope of manufacture and supply of natural latex and nitrile latex examination gloves. The Group's proprietary brand of products conforms to various international standards and requirements.

The Group also has a strategic investment in the joint development, management, and operation of active retirement homes in Malaysia.

For more information, please visit the Company's website at www.ughealthcarecorporation.com.

Issued for and on behalf of **UG Healthcare Corporation Limited** by:

富登财经 FinComm
OCTAVE

Investor relations contact:

Rosalina Soh 苏沛熙
Mobile : (65) 9677 6683
Email : rosalina@octavecomms.com

*This media release has been reviewed by the Company's sponsor, SAC Capital Private Limited (the "**Sponsor**").*

*This media release has not been examined or approved by the Singapore Exchange Securities Trading Limited ("**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this media release, including the correctness of any of the statements or opinions made or reports contained in this media release.*

The contact person for the Sponsor is Mr. Bernard Lim (Telephone: +65 6232 3232) at 1 Robinson Road, #21-01 AIA Tower, Singapore 048542.